<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="173608">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835900</url>
  </required_header>
  <id_info>
    <org_study_id>I 136208</org_study_id>
    <secondary_id>Pfizer IIR-GA30523</secondary_id>
    <nct_id>NCT00835900</nct_id>
    <nct_alias>NCT00957515</nct_alias>
  </id_info>
  <brief_title>An Alternative Dosing Schedule of Varenicline for Smoking Cessation</brief_title>
  <official_title>Extended Varenicline for Smoking Cessation: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the use of an prolonged alternative dosing schedule
      using varenicline for smoking cessation leading to greater quit rates and higher rates of
      continuous abstinence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study will utilize a two group randomized design. Adult smokers who are motivated
      to quit smoking will be randomized to one of two treatment groups. Both groups will receive
      brief support counseling. During a one-week baseline and the 4-week pre-quit period smoking
      rate, smoking satisfaction, withdrawal, and craving will be assessed on a daily basis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in smoking behavior, as well as smoking satisfaction, craving, and withdrawal.</measure>
    <time_frame>daily</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of smoking cessation.</measure>
    <time_frame>12 weeks after quit date.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug plus counseling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo plus counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline</intervention_name>
    <description>variable dosing schedule</description>
    <arm_group_label>varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  currently smoking at least 15 cigarettes daily

          -  in good health

          -  able to read and speak English fluently

          -  have a home telephone and plan to reside in Western New York for 6 months

          -  willing to make quit attempt

          -  signed informed consent

          -  who planned quit attempt.

        Exclusion Criteria:

          -  serious medical condition

          -  depression or mental health condition requiring treatment in the past year

          -  history of panic disorder, psychosis, bipolar disorder

          -  alcohol or drug abuse in the past year

          -  use of tobacco products other than cigarettes

          -  current use of other cessation pharmacotherapies

          -  pregnancy/planned pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin C Mahoney, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 11, 2015</lastchanged_date>
  <firstreceived_date>February 3, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking cessation</keyword>
  <keyword>varenicline</keyword>
  <keyword>smoking cessation treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
